Closer Look: Gov't Controls Partly to Blame for Graft by Foreign Pharmaceuticals

The investigation into British drug maker GlaxoSmithKline Plc. (GSK) has caused the public to be concerned about a graft network involving foreign pharmaceuticals in China and triggered debate about the country's pricing of medicines.

The inquiry has found a large amount of gray spending at GSK that was used to bribe officials, doctors and medical associations in order to expand the company's market share in the country and boost the prices of its medicines.